Neurocrine Biosciences, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64125C1099
USD
165.24
2.12 (1.3%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Net Sales
814.50
805.50
794.90
687.50
572.60
627.70
622.10
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
814.50
805.50
794.90
687.50
572.60
627.70
622.10
Raw Material Cost
13.80
17.60
14.00
11.30
9.20
15.50
13.60
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
318.50
301.80
291.60
286.30
276.50
287.80
234.30
Other Expenses
29.62
25.82
25.00
24.43
26.32
17.94
18.94
Total Expenditure (Excl Depreciation)
628.50
577.60
555.60
541.90
548.90
482.70
437.30
Operating Profit (PBDIT) excl Other Income
186
227.89999999999998
239.3
145.6
23.700000000000003
145
184.8
Other Income
56.70
25.80
22.20
20.60
21.70
22.50
23.40
Operating Profit (PBDIT)
250.00
261.20
269.20
173.50
53.00
174.60
214.70
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Exceptional Items
4.10
-14.30
30.30
-6.70
-30.70
-4.90
-17.90
Gross Profit (PBDT)
800.70
787.90
780.90
676.20
563.40
612.20
608.50
Depreciation
7.30
7.50
7.70
7.30
7.60
7.10
6.50
Profit Before Tax
246.80
239.40
291.80
159.50
14.70
162.60
190.30
Tax
48.90
85.70
82.30
52.00
6.80
59.50
60.50
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
197.90
153.70
209.50
107.50
7.90
103.10
129.80
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
197.90
153.70
209.50
107.50
7.90
103.10
129.80
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
197.90
153.70
209.50
107.50
7.90
103.10
129.80
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
3,407.40
3,253.10
3,003.60
2,694.30
2,535.70
2,589.70
2,718.90
Earnings per share (EPS)
1.91
1.48
2.04
1.06
0.08
1.0
1.24
Diluted Earnings per share
1.91
1.48
2.04
1.06
0.08
1.0
1.24
Operating Profit Margin (Excl OI)
22.84%
28.29%
30.1%
21.18%
4.14%
23.1%
29.71%
Gross Profit Margin
31.2%
30.65%
37.68%
24.26%
3.89%
27.04%
31.63%
PAT Margin
24.3%
19.08%
26.36%
15.64%
1.38%
16.43%
20.86%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2026 is 42.25% vs 11.12% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is 2,405.06% vs -81.80% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 517.57% vs -71.93% in Mar 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Neurocrine Biosciences, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
814.50
730.80
83.70
11.45%
Other Operating Income
0.00
0.00
0.00
Total Operating income
814.50
730.80
83.70
11.45%
Raw Material Cost
13.80
119.36
-105.56
-88.44%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
36.41
-36.41
-100.00%
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
21.71
-21.71
-100.00%
Selling and Distribution Expenses
318.50
99.05
219.45
221.55%
Other Expenses
29.62
9.58
20.04
209.19%
Total Expenditure (Excl Depreciation)
628.50
372.37
256.13
68.78%
Operating Profit (PBDIT) excl Other Income
186.00
358.43
-172.43
-48.11%
Other Income
56.70
8.17
48.53
594.00%
Operating Profit (PBDIT)
250.00
380.30
-130.30
-34.26%
Interest
0.00
21.71
-21.71
-100.00%
Exceptional Items
4.10
-1.71
5.81
339.77%
Gross Profit (PBDT)
800.70
611.44
189.26
30.95%
Depreciation
7.30
13.70
-6.40
-46.72%
Profit Before Tax
246.80
343.17
-96.37
-28.08%
Tax
48.90
12.21
36.69
300.49%
Provisions and contingencies
0
0
0.00
Profit After Tax
197.90
330.96
-133.06
-40.20%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
197.90
330.96
-133.06
-40.20%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
197.90
330.96
-133.06
-40.20%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
3,407.40
1,505.10
1,902.30
126.39%
Earnings per share (EPS)
1.91
2.88
-0.97
-33.68%
Diluted Earnings per share
1.91
2.88
-0.97
-33.68%
Operating Profit Margin (Excl OI)
22.84%
49.05%
0.00
-26.21%
Gross Profit Margin
31.20%
48.83%
0.00
-17.63%
PAT Margin
24.30%
45.29%
0.00
-20.99%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 81.45 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 1.12% vs 1.33% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 42.25% vs 11.12% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 19.79 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 28.76% vs -26.63% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 2,405.06% vs -81.80% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 19.33 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -17.88% vs -4.70% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 517.57% vs -71.93% in Mar 2025

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 22.84%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025